Novo Nordisk (NVO) vs. Solventum (SOLV)
This page compares Novo Nordisk (NVO) with Solventum (SOLV) using performance and risk, profitability, financial strength, growth, dividends, and valuation metrics.
Company Profile
Novo Nordisk (NVO) and Solventum (SOLV) share the Health Care sector but sit in different industry groups — NVO in Pharmaceuticals, Biotechnology & Life Sciences and SOLV in Health Care Equipment & Services.
Novo Nordisk (NVO) carries decades of public-market history since April 30, 1981, while Solventum (SOLV) listed on March 26, 2024 — long-window comparisons have far more historical data on the NVO side.
Solventum (SOLV) trades as a standard ordinary-equity line, while Novo Nordisk (NVO) is an ADR tied to a foreign-share or depositary-receipt structure — compare with FX exposure, program fees, and dividend-withholding-tax differences in mind.
| Symbol | NVO | SOLV |
|---|---|---|
| Name | Novo Nordisk A/S Sponsored ADR | Solventum Corporation |
| Country/Region | Denmark | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Health Care Equipment & Services |
| GICS Industry | Pharmaceuticals | Health Care Equipment & Supplies |
| GICS Sub-Industry | Pharmaceuticals | Health Care Supplies |
| Market Capitalization | 190.31 billion USD | 14.03 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | April 30, 1981 | March 26, 2024 |
| Security Type | ADR | Common Stock |
Valuation
Price-to-Earnings Ratio (TTM)
Both Novo Nordisk (NVO) at 10.08 and Solventum (SOLV) at 9.92 trade in the lower-multiple quartile for Price-to-Earnings Ratio (TTM) among industry peers, indicating lower trailing earnings multiples than typical peers.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.08
- Max
- 76.34
- Q3
- 42.08
- Median
- 25.10
- Q1
- 14.48
- Min
- 1.55
SOLV
Health Care Equipment & Services industry group
9.92
- Max
- 74.55
- Q3
- 42.60
- Median
- 27.79
- Q1
- 18.85
- Min
- 0.80
Price-to-Sales Ratio (TTM)
Novo Nordisk (NVO) at 0.58 sits in the cheaper Price-to-Sales Ratio (TTM) quartile while Solventum (SOLV) at 1.70 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.58
- Max
- 51.32
- Q3
- 22.55
- Median
- 6.57
- Q1
- 3.36
- Min
- 0.01
SOLV
Health Care Equipment & Services industry group
1.70
- Max
- 8.67
- Q3
- 4.11
- Median
- 1.92
- Q1
- 0.95
- Min
- 0.03
Price-to-Book Ratio (MRQ)
On Price-to-Book Ratio (MRQ), both Novo Nordisk (NVO) at 6.05 and Solventum (SOLV) at 2.78 are valued close to their industries’ norm against book — neither stands out from peers.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.05
- Max
- 12.58
- Q3
- 6.24
- Median
- 3.34
- Q1
- 1.64
- Min
- -3.91
SOLV
Health Care Equipment & Services industry group
2.78
- Max
- 10.87
- Q3
- 5.31
- Median
- 2.71
- Q1
- 1.44
- Min
- -1.82
Valuation at a Glance
| Symbol | NVO | SOLV |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 10.08 | 9.92 |
| Price-to-Sales Ratio (TTM) | 0.58 | 1.70 |
| Price-to-Book Ratio (MRQ) | 6.05 | 2.78 |
| Free Cash Flow Yield | -6.33% | 2.70% |
Profitability
Return on Equity (TTM)
Both Novo Nordisk (NVO) at 71.40% and Solventum (SOLV) at 34.80% rank in the top quartile for Return on Equity (TTM) among industry peers, indicating strong returns on shareholders’ equity.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
71.40%
- Max
- 99.40%
- Q3
- 2.92%
- Median
- -31.42%
- Q1
- -61.80%
- Min
- -158.89%
SOLV
Health Care Equipment & Services industry group
34.80%
- Max
- 53.65%
- Q3
- 13.46%
- Median
- 3.62%
- Q1
- -17.72%
- Min
- -59.21%
Net Profit Margin (TTM)
Novo Nordisk (NVO) at 37.21% keeps the most of each sales dollar — above its industry’s Net Profit Margin (TTM) range — and Solventum (SOLV) at 17.33% also retains a top-quartile share.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.21%
- Max
- 13.59%
- Q3
- 4.00%
- Median
- 0.00%
- Q1
- -2.47%
- Min
- -11.53%
SOLV
Health Care Equipment & Services industry group
17.33%
- Max
- 30.40%
- Q3
- 7.97%
- Median
- 1.52%
- Q1
- -9.70%
- Min
- -34.34%
Operating Profit Margin (TTM)
Novo Nordisk (NVO) at 61.57% operates in the top Operating Profit Margin (TTM) quartile, ahead of Solventum (SOLV) at 5.58%, which runs around its industry’s norm.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
61.57%
- Max
- 100.30%
- Q3
- 4.49%
- Median
- 0.00%
- Q1
- -127.25%
- Min
- -313.85%
SOLV
Health Care Equipment & Services industry group
5.58%
- Max
- 37.54%
- Q3
- 12.86%
- Median
- 5.48%
- Q1
- -4.58%
- Min
- -25.61%
Profitability at a Glance
| Symbol | NVO | SOLV |
|---|---|---|
| Return on Equity (TTM) | 71.40% | 34.80% |
| Return on Assets (TTM) | 19.25% | 2.75% |
| Net Profit Margin (TTM) | 37.21% | 17.33% |
| Operating Profit Margin (TTM) | 61.57% | 5.58% |
| Gross Profit Margin (TTM) | 83.20% | 53.66% |
Growth
Revenue Growth
Revenue Growth at a Glance
| Symbol | NVO | SOLV |
|---|---|---|
| 1-Year Revenue Growth | 6.43% | 0.86% |
| 3-Year Revenue CAGR | 20.43% | 0.79% |
EPS Growth
EPS Growth at a Glance
| Symbol | NVO | SOLV |
|---|---|---|
| 1-Year EPS Growth | 1.77% | 221.74% |
| 3-Year EPS CAGR | 23.52% | 4.51% |
Financial Strength
Current Ratio (MRQ)
Both Novo Nordisk (NVO) at 0.79 and Solventum (SOLV) at 1.07 run Current Ratio (MRQ) in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.79
- Max
- 24.81
- Q3
- 11.82
- Median
- 5.63
- Q1
- 2.69
- Min
- 0.23
SOLV
Health Care Equipment & Services industry group
1.07
- Max
- 7.79
- Q3
- 4.27
- Median
- 2.03
- Q1
- 1.34
- Min
- 0.04
Debt-to-Equity Ratio (MRQ)
Both Novo Nordisk (NVO) at 0.72 and Solventum (SOLV) at 1.06 run Debt-to-Equity Ratio (MRQ) in the higher-leverage quartile of industry peers, indicating more debt relative to equity than typical competitors.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.72
- Max
- 1.60
- Q3
- 0.68
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
SOLV
Health Care Equipment & Services industry group
1.06
- Max
- 2.02
- Q3
- 0.99
- Median
- 0.60
- Q1
- 0.16
- Min
- 0.00
Financial Strength at a Glance
| Symbol | NVO | SOLV |
|---|---|---|
| Current Ratio (MRQ) | 0.79 | 1.07 |
| Debt-to-Equity Ratio (MRQ) | 0.72 | 1.06 |
| Net Debt / EBITDA | 0.72 | 4.21 |
Dividends
Dividend Yield (TTM)
Solventum (SOLV) pays no dividend (yield 0.00%) — often a deliberate choice to reinvest earnings rather than return cash. Meanwhile Novo Nordisk (NVO) reports a yield of 4.19%, ranking against industry peers normally.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.19%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SOLV
Health Care Equipment & Services industry group
0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Solventum (SOLV) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a payout of 42.59%, ranking against industry peers normally.
NVO
Pharmaceuticals, Biotechnology & Life Sciences industry group
42.59%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SOLV
Health Care Equipment & Services industry group
0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividends at a Glance
| Symbol | NVO | SOLV |
|---|---|---|
| Dividend Yield (TTM) | 4.19% | 0.00% |
| Dividend Payout Ratio (TTM) | 42.59% | 0.00% |
Performance & Risk
Performance & Risk at a Glance
| Symbol | NVO | SOLV |
|---|---|---|
| 1-Year Return | -38.01% | 7.48% |
| 1-Year Volatility | 51.98% | 27.30% |
| Beta | 0.78 | 0.63 |
| 3-Month Avg. Volume | 16.33M | 1.69M |